February 24, 2020
1 min read

A Phase I Clinical Trial of T Cells Expressing a Novel Fully Human Anti-BCMA CAR for Treating Multiple Myeloma

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Phase 1, interventional, open-label dose-escalation study to determine the safety and feasibility of administering T cells expressing an anti-BCMA CAR to patients with multiple myeloma.